• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
CHEN Xi,YOU Meigui,TIAN Hua,CHEN Xiaoyi,LIN Min,LAN Xingpeng.Research progress of thrombolytic therapy for acute ischemic stroke[J].Journal Of Pharmaceutical Research,2022,41(8):537-540[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 2587times   Download 2166次 QR Code for this article
Scan with your phone!
急性缺血性脑卒中溶栓治疗的研究进展
陈曦1,尤梅桂1,2,田华1,2,陈潇怡1,林敏1,兰兴鹏1
Font:Larger+|Default|Smaller-
(1.厦门医学院基础医学部,福建 厦门 361023;2.厦门医学院机能与临床转化福建省高校重点实验室,福建 厦门 361023)
摘要:
脑卒中是我国成年人致死、致残的重要病因之一,具有发病率高、复发率高、致残和死亡率高的特点。目前早期溶栓治疗是被广泛认可且积极有效的主要治疗方式。而溶栓药物重组组织纤溶酶原激活剂(rt-PA)是FDA批准的唯一缺血性脑卒中药物,但在临床使用中有诸多限制。近年来临床上关于溶栓治疗的研究发展迅速,本文将对急性缺血性脑卒中(acute ischemic stroke,AIS)的溶栓治疗进行归纳和总结,以期为AIS药物治疗提供思路。
关键词:  脑卒中  动脉溶栓  静脉溶栓  溶栓治疗
DOI:10.13506/j.cnki.jpr.2022.08.010
基金项目:福建省中青年教师教育科研项目(No.JT180653);厦门医学院大学生创新训练项目(No.X202112631039);厦门医学院大学生创新训练项目(No.X202112631054)
Publication Date:August 25, 2022
Research progress of thrombolytic therapy for acute ischemic stroke
CHEN Xi1,YOU Meigui1,2,TIAN Hua1,2,CHEN Xiaoyi1,LIN Min1,LAN Xingpeng1
(1. Department of Basic Medicine, Xiamen Medical College, Xiamen 361023,China;2. Key laboratory of functional and clinical translational medicine,Fujian Province University,Xiamen 361023,China)
Abstract:
Stroke is one of the important causes of death and disability among adults in our country. It has the characteristics of high morbidity, recurrence, disability and mortality. At present, early thrombolysis is a widely recognized and effective main treatment modality. The thrombolytic drug recombinant tissue plasminogen activator (rt-PA) is the only ischemic stroke drug approved by the FDA, but it has many limitations in clinical use. In recent years, clinical research on thrombolytic therapy has developed rapidly. This article summarized the thrombolytic therapy of acute ischemic stroke (AIS) in order to provide ideas for the drug treatment of AIS.
Key words:  Stroke  Arterial thrombolysis  Intravenous thrombolysis  Thrombolytic therapy
Today's Visits:509    Total Visits:2383239
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.